Table 5 Blocking of Cytotoxicity of CD4+T Cells Toward IFN-γ-Stimulated Thyrocytes
Treatment of thyrocytes with mAb/hFas-Fc | Concentration of mAb/hFas-Fc (μg/ml) | ||||
---|---|---|---|---|---|
0 | 2.5 | 5 | 10 | 20 | |
(−) | 56.5 ± 4.6 | ||||
control IgG | NT | 56.9 ± 4.9 | 57.2 ± 5.1 | 58.0 ± 5.0 | |
anti-HLA-ABC | NT | 54.9 ± 4.6 | 55.0 ± 5.1 | 57.0 ± 3.9 | |
anti-HLA-DR and -DQ | NT | 18.8 ± 1.1 | 12.7 ± 1.0 | 12.2 ± 0.9 | |
hFas-Fc | NT | 35.9 ± 2.1 | 27.1 ± 1.5 | 27.9 ± 1.9 | |
anti-FasL | 26.9 ± 1.7 | 25.5 ± 1.9 | 24.9 ± 1.5 | NT | |
anti-CD54 | NT | 33.7 ± 1.7 | 28.5 ± 1.7 | 28.0 ± 1.4 | |
anti-CD58 | NT | 39.9 ± 2.0 | 33.7 ± 2.2 | 33.0 ± 1.5 | |
anti-CD54 and -CD58 | NT | 18.1 ± 1.0 | 11.9 ± 1.2 | 10.9 ± 1.3 | |
anti-TNF-α | NT | 55.9 ± 4.2 | 52.9 ± 3.9 | 54.0 ± 2.9 | |
anti-IL-1β | NT | 54.3 ± 3.2 | 54.0 ± 4.2 | 54.7 ± 2.7 |